Drug Trial Radar · NCT07693231
A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or Overweight
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
48
Actual
Start
Jul 21, 2026
Primary completion
Dec 22, 2026
Study completion Jan 5, 2027
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jul 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Part 1: To investigate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BI 3034701 in Japanese male and female participants with body mass index (BMI) ≥27.0 kg/m² or more following subcutaneous administration of multiple rising doses over 16 weeks. Part 2: To investigate safety, tolerability, and PK of BI 3034701 in Japanese male and female healthy participants with BMI ≥23.0 to \<27.0 kg/m² following subcutaneous administration of multiple rising doses over 7 weeks.
Conditions
- Healthy
- Obesity
Interventions
BI 3034701Drug
BI 3034701
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigatorTime frame: Part 1: up to Week 19, Part 2: up to Week 10
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
SOUSEIKAI Hakata Clinic
Fukuoka, Fukuoka, Japan
Fukuoka Mirai Hospital
Fukuoka, Fukuoka, Japan
SOUSEIKAI Sumida Hospital
Tokyo, Sumida-ku, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.